keyword
MENU ▼
Read by QxMD icon Read
search

clinical features of Alzheimer

keyword
https://www.readbyqxmd.com/read/28447569/a-new-treatment-strategy-for-parkinson-s-disease-through-the-gut-brain-axis-the-glucagon-like-peptide-1-receptor-pathway
#1
Dong Seok Kim, Ho-Il Choi, Yun Wang, Yu Luo, Barry J Hoffer, Nigel H Greig
Molecular communications in the gut-brain axis, between the central nervous system and the gastrointestinal tract, arecritical for maintaining healthy brain function particularly in aging. Epidemiological analyses indicate type 2 diabetes mellitus (T2DM) is a risk factor for neurodegenerative disorders, including Alzheimer's disease (AD) and Parkinson's diseases (PD) for which aging shows a major correlative association. Common pathophysiological features exist between T2DM, AD and PD, including oxidative stress, inflammation, insulin resistance, abnormal protein processing and cognitive decline, and suggest that effective drugs for T2DM that positively impact the gut-brain axis could provide an effective treatment option for neurodegenerative diseases...
April 26, 2017: Cell Transplantation
https://www.readbyqxmd.com/read/28434655/apolipoprotein-e-receptors-and-modulation-of-alzheimer-s-disease
#2
REVIEW
Na Zhao, Chia-Chen Liu, Wenhui Qiao, Guojun Bu
Apolipoprotein E (apoE) is a lipid carrier in both the peripheral and the central nervous systems. Lipid-loaded apoE lipoprotein particles bind to several cell surface receptors to support membrane homeostasis and injury repair in the brain. Considering prevalence and relative risk magnitude, the ε4 allele of the APOE gene is the strongest genetic risk factor for late-onset Alzheimer's disease (AD). ApoE4 contributes to AD pathogenesis by modulating multiple pathways, including but not limited to the metabolism, aggregation, and toxicity of amyloid-β peptide, tauopathy, synaptic plasticity, lipid transport, glucose metabolism, mitochondrial function, vascular integrity, and neuroinflammation...
March 14, 2017: Biological Psychiatry
https://www.readbyqxmd.com/read/28428166/vascular-cognitive-impairment-in-a-memory-clinic-population-rationale-and-design-of-the-utrecht-amsterdam-clinical-features-and-prognosis-in-vascular-cognitive-impairment-trace-vci-study
#3
EDITORIAL
Jooske Marije Funke Boomsma, Lieza Geertje Exalto, Frederik Barkhof, Esther van den Berg, Jeroen de Bresser, Rutger Heinen, Huiberdina Lena Koek, Niels Daniël Prins, Philip Scheltens, Henry Chanoch Weinstein, Wiesje Maria van der Flier, Geert Jan Biessels
BACKGROUND: Vascular Cognitive Impairment (VCI) refers to cognitive dysfunction due to vascular brain injury, as a single cause or in combination with other, often neurodegenerative, etiologies. VCI is a broad construct that captures a heterogeneous patient population both in terms of cognitive and noncognitive symptoms and in terms of etiology and prognosis. This provides a challenge when applying this construct in clinical practice. OBJECTIVE: This paper presents the rationale and design of the TRACE-VCI study, which investigates the clinical features and prognosis of VCI in a memory clinic setting...
April 19, 2017: JMIR Research Protocols
https://www.readbyqxmd.com/read/28414186/a-review-on-neuroimaging-based-classification-studies-and-associated-feature-extraction-methods-for-alzheimer-s-disease-and-its-prodromal-stages
#4
REVIEW
Saima Rathore, Mohamad Habes, Muhammad Aksam Iftikhar, Amanda Shacklett, Christos Davatzikos
Neuroimaging has made it possible to measure pathological brain changes associated with Alzheimer's disease (AD) in vivo. Over the past decade, these measures have been increasingly integrated into imaging signatures of AD by means of classification frameworks, offering promising tools for individualized diagnosis and prognosis. We reviewed neuroimaging-based studies for AD classification and mild cognitive impairment, selected after online database searches in Google Scholar and PubMed (January, 1985 to June, 2016)...
April 13, 2017: NeuroImage
https://www.readbyqxmd.com/read/28410662/lewy-body-disorders
#5
REVIEW
Douglas Galasko
Dementia syndromes associated with Lewy bodies are subdivided into dementia with Lewy bodies (DLB), an underdiagnosed cause of dementia in the elderly, and Parkinson disease with dementia (PDD), cognitive impairment appearing in people diagnosed with Parkinson disease. Their neuropathologic substrates are the widespread distribution of aggregates of the protein α-synuclein in neurons in cortical brain regions, accompanied by variable Alzheimer pathology. Clinical features of DLB and PDD include distinctive changes in cognition, behavior, movement, sleep, and autonomic function...
May 2017: Neurologic Clinics
https://www.readbyqxmd.com/read/28404458/a-comparison-of-accurate-automatic-hippocampal-segmentation-methods
#6
Azar Zandifar, Vladimir Fonov, Pierrick Coupé, Jens Pruessner, D Louis Collins
The hippocampus is one of the first brain structures affected by Alzheimer's disease (AD). While many automatic methods for hippocampal segmentation exist, few studies have compared them on the same data. In this study, we compare four fully automated hippocampal segmentation methods in terms of their conformity with manual segmentation and their ability to be used as an AD biomarker in clinical settings. We also apply error correction to the four automatic segmentation methods, and complete a comprehensive validation to investigate differences between the methods...
April 9, 2017: NeuroImage
https://www.readbyqxmd.com/read/28391822/a-novel-method-and-software-for-automatically-classifying-alzheimer-s-disease-patients-by-magnetic-resonance-imaging-analysis
#7
F Previtali, P Bertolazzi, G Felici, E Weitschek
BACKGROUND AND OBJECTIVE: The cause of the Alzheimer's disease is poorly understood and to date no treatment to stop or reverse its progression has been discovered. In developed countries, the Alzheimer's disease is one of the most financially costly diseases due to the requirement of continuous treatments as well as the need of assistance or supervision with the most cognitively demanding activities as time goes by. The objective of this work is to present an automated approach for classifying the Alzheimer's disease from magnetic resonance imaging (MRI) patient brain scans...
May 2017: Computer Methods and Programs in Biomedicine
https://www.readbyqxmd.com/read/28385651/intranasal-telmisartan-ameliorates-brain-pathology-in-five-familial-alzheimer-s-disease-mice
#8
Nofar Torika, Keren Asraf, Hagit Cohen, Sigal Fleisher-Berkovich
The renin-angiotensin system (RAS) is a major circulative system engaged in homeostasis modulation. Angiotensin II (Ang II) serves as its main effector hormone upon binding to its primary receptor, Ang II receptor type 1 (AT1R). It is well established that an intrinsic independent brain RAS exists. Abnormal AT1R activation both in the periphery and in the brain probably contributes to the development of Alzheimer's disease (AD) pathology that is characterized, among others, by brain inflammation. Moreover, treatment with drugs that block AT1R (AT1R blockers, ARBs) ameliorates most of the clinical risk factors leading to AD...
April 3, 2017: Brain, Behavior, and Immunity
https://www.readbyqxmd.com/read/28382615/a-case-of-multiple-system-atrophy-with-preexisting-alzheimer-s-disease-and-predating-the-hot-cross-bun-sign
#9
Chi-Wei Lin, Chi-Yu Tseng, Chung-Ping Lo, Min-Chien Tu
PURPOSE: Synucleinopathy, tauopathy and amyloidopathy were classified as distinct clinical and pathological entities in traditional classification systems, and their interactions have been studied on neuropathology and molecular genetics recently. CASE REPORT: In this report, we present a 69-year-old male patient who had been diagnosed with probable Alzheimer's disease (AD) dementia due to progressive forgetfulness in February 2013. His Mini- Mental State Examination score was 21/30, and his Cognitive Abilities Screening Instrument score was 78/100, resulted from profound deficits in recent memory and abstract thinking domains...
December 15, 2016: Acta Neurologica Taiwanica
https://www.readbyqxmd.com/read/28374014/transgenic-monkey-model-of-the-polyglutamine-diseases-recapitulating-progressive-neurological-symptoms
#10
Ikuo Tomioka, Hidetoshi Ishibashi, Eiko N Minakawa, Hideyuki H Motohashi, Osamu Takayama, Yuko Saito, H Akiko Popiel, Sandra Puentes, Kensuke Owari, Terumi Nakatani, Naotake Nogami, Kazuhiro Yamamoto, Satoru Noguchi, Takahiro Yonekawa, Yoko Tanaka, Naoko Fujita, Hikaru Suzuki, Hisae Kikuchi, Shu Aizawa, Seiichi Nagano, Daisuke Yamada, Ichizo Nishino, Noritaka Ichinohe, Keiji Wada, Shinichi Kohsaka, Yoshitaka Nagai, Kazuhiko Seki
Age-associated neurodegenerative diseases, such as Alzheimer's disease, Parkinson's disease, and the polyglutamine (polyQ) diseases, are becoming prevalent as a consequence of elongation of the human lifespan. Although various rodent models have been developed to study and overcome these diseases, they have limitations in their translational research utility owing to differences from humans in brain structure and function and in drug metabolism. Here, we generated a transgenic marmoset model of the polyQ diseases, showing progressive neurological symptoms including motor impairment...
March 2017: ENeuro
https://www.readbyqxmd.com/read/28369170/supervised-multiblock-sparse-multivariable-analysis-with-application-to-multimodal-brain-imaging-genetics
#11
Atsushi Kawaguchi, Fumio Yamashita
This article proposes a procedure for describing the relationship between high-dimensional data sets, such as multimodal brain images and genetic data. We propose a supervised technique to incorporate the clinical outcome to determine a score, which is a linear combination of variables with hieratical structures to multimodalities. This approach is expected to obtain interpretable and predictive scores. The proposed method was applied to a study of Alzheimer's disease (AD). We propose a diagnostic method for AD that involves using whole-brain magnetic resonance imaging (MRI) and positron emission tomography (PET), and we select effective brain regions for the diagnostic probability and investigate the genome-wide association with the regions using single nucleotide polymorphisms (SNPs)...
March 19, 2017: Biostatistics
https://www.readbyqxmd.com/read/28364127/-two-level-measurements-of-processing-speed-as-cognitive-markers-in-the-differential-diagnosis-of-dsm-5-mild-neurocognitive-disorders-ncd
#12
Hanna Lu, Sandra S M Chan, Linda C W Lam
Processing speed is an updated diagnostic factor for neurocognitive disorders (NCD) in DSM-5. This study investigated the characteristics of processing speed and their diagnostic values in NCD patients. A flanker test was conducted in 31 adults with NCD due to vascular disease (NCD-vascular), 36 patients with NCD due to Alzheimer's disease (NCD-AD), and 137 healthy controls. The processing speed was evaluated using two measurements: mean reaction time (RT) and intra-individual variability of RT. Mean RT represents the global processing speed...
March 31, 2017: Scientific Reports
https://www.readbyqxmd.com/read/28362514/preclinical-to-phase-ii-amyloid-beta-a%C3%AE-peptide-modulators-under-investigation-for-alzheimer-s-disease
#13
Chris G Parsons, Gerhard Rammes
Alzheimer disease (AD) is the most common form of dementia and its incidence is increasing at an alarming rate all over the world. The pathophysiology of AD is characterized by chronic, progressive neurodegeneration which involves early synaptotoxicity. One of the most obvious pathological feature of AD is the accumulation of amyloid-β (Aβ) in the brain. Since current treatment options only provide symptomatic help and Aβ is thought to underlie early synaptic pathology, Aβ reduction or modulation in the brain may be a promising therapeutic strategy in preventing and /or reversing AD-related dysfunction...
May 2017: Expert Opinion on Investigational Drugs
https://www.readbyqxmd.com/read/28352227/a-novel-genetic-screen-identifies-modifiers-of-age-dependent-amyloid-%C3%AE-toxicity-in-the-drosophila-brain
#14
Lautaro F Belfiori-Carrasco, María S Marcora, Nadia I Bocai, M Fernanda Ceriani, Laura Morelli, Eduardo M Castaño
The accumulation of amyloid β peptide (Aβ) in the brain of Alzheimer's disease (AD) patients begins many years before clinical onset. Such process has been proposed to be pathogenic through the toxicity of Aβ soluble oligomers leading to synaptic dysfunction, phospho-tau aggregation and neuronal loss. Yet, a massive accumulation of Aβ can be found in approximately 30% of aged individuals with preserved cognitive function. Therefore, within the frame of the "amyloid hypothesis", compensatory mechanisms and/or additional neurotoxic or protective factors need to be considered and investigated...
2017: Frontiers in Aging Neuroscience
https://www.readbyqxmd.com/read/28352155/proteinopathy-oxidative-stress-and-mitochondrial-dysfunction-cross-talk-in-alzheimer-s-disease-and-parkinson-s-disease
#15
REVIEW
Gargi Ganguly, Sasanka Chakrabarti, Uttara Chatterjee, Luciano Saso
Alzheimer's disease and Parkinson's disease are two common neurodegenerative diseases of the elderly people that have devastating effects in terms of morbidity and mortality. The predominant form of the disease in either case is sporadic with uncertain etiology. The clinical features of Parkinson's disease are primarily motor deficits, while the patients of Alzheimer's disease present with dementia and cognitive impairment. Though neuronal death is a common element in both the disorders, the postmortem histopathology of the brain is very characteristic in each case and different from each other...
2017: Drug Design, Development and Therapy
https://www.readbyqxmd.com/read/28346578/association-of-plasma-neurofilament-light-with-neurodegeneration-in-patients-with-alzheimer-disease
#16
Niklas Mattsson, Ulf Andreasson, Henrik Zetterberg, Kaj Blennow
Importance: Existing cerebrospinal fluid (CSF) or imaging (tau positron emission tomography) biomarkers for Alzheimer disease (AD) are invasive or expensive. Biomarkers based on standard blood test results would be useful in research, drug development, and clinical practice. Plasma neurofilament light (NFL) has recently been proposed as a blood-based biomarker for neurodegeneration in dementias. Objective: To test whether plasma NFL concentrations are increased in AD and associated with cognitive decline, other AD biomarkers, and imaging evidence of neurodegeneration...
March 27, 2017: JAMA Neurology
https://www.readbyqxmd.com/read/28346104/bioengineered-3d-glial-cell-culture-systems-and-applications-for-neurodegeneration-and-neuroinflammation
#17
P Marc D Watson, Edel Kavanagh, Gary Allenby, Matthew Vassey
Neurodegeneration and neuroinflammation are key features in a range of chronic central nervous system (CNS) diseases such as Alzheimer's and Parkinson's disease, as well as acute conditions like stroke and traumatic brain injury, for which there remains significant unmet clinical need. It is now well recognized that current cell culture methodologies are limited in their ability to recapitulate the cellular environment that is present in vivo, and there is a growing body of evidence to show that three-dimensional (3D) culture systems represent a more physiologically accurate model than traditional two-dimensional (2D) cultures...
February 1, 2017: SLAS Discovery
https://www.readbyqxmd.com/read/28341160/metabolic-network-failures-in-alzheimer-s-disease-a-biochemical-road%C3%A2-map
#18
Jon B Toledo, Matthias Arnold, Gabi Kastenmüller, Rui Chang, Rebecca A Baillie, Xianlin Han, Madhav Thambisetty, Jessica D Tenenbaum, Karsten Suhre, J Will Thompson, Lisa St John-Williams, Siamak MahmoudianDehkordi, Daniel M Rotroff, John R Jack, Alison Motsinger-Reif, Shannon L Risacher, Colette Blach, Joseph E Lucas, Tyler Massaro, Gregory Louie, Hongjie Zhu, Guido Dallmann, Kristaps Klavins, Therese Koal, Sungeun Kim, Kwangsik Nho, Li Shen, Ramon Casanova, Sudhir Varma, Cristina Legido-Quigley, M Arthur Moseley, Kuixi Zhu, Marc Y R Henrion, Sven J van der Lee, Amy C Harms, Ayse Demirkan, Thomas Hankemeier, Cornelia M van Duijn, John Q Trojanowski, Leslie M Shaw, Andrew J Saykin, Michael W Weiner, P Murali Doraiswamy, Rima Kaddurah-Daouk
INTRODUCTION: The Alzheimer's Disease Research Summits of 2012 and 2015 incorporated experts from academia, industry, and nonprofit organizations to develop new research directions to transform our understanding of Alzheimer's disease (AD) and propel the development of critically needed therapies. In response to their recommendations, big data at multiple levels are being generated and integrated to study network failures in disease. We used metabolomics as a global biochemical approach to identify peripheral metabolic changes in AD patients and correlate them to cerebrospinal fluid pathology markers, imaging features, and cognitive performance...
March 21, 2017: Alzheimer's & Dementia: the Journal of the Alzheimer's Association
https://www.readbyqxmd.com/read/28332351/metabolism-centric-overview-of-the-pathogenesis-of-alzheimer-s-disease
#19
REVIEW
Somang Kang, Yong Ho Lee, Jong Eun Lee
Alzheimer's disease (AD) is a degenerative brain disease and the most common cause of dementia. AD is characterized by the extracellular amyloid beta (Aβ) plaques and intraneuronal deposits of neurofibrillary tangles (NFTs). Recently, as aging has become a familiar phenomenon around the world, patients with AD are increasing in number. Thus, many researchers are working toward finding effective therapeutics for AD focused on Aβ hypothesis, although there has been no success yet. In this review paper, we suggest that AD is a metabolic disease and that we should focus on metabolites that are affected by metabolic alterations to find effective therapeutics for AD...
May 2017: Yonsei Medical Journal
https://www.readbyqxmd.com/read/28323825/association-between-fatty-acid-metabolism-in-the-brain-and-alzheimer-disease-neuropathology-and-cognitive-performance-a-nontargeted-metabolomic-study
#20
Stuart G Snowden, Amera A Ebshiana, Abdul Hye, Yang An, Olga Pletnikova, Richard O'Brien, John Troncoso, Cristina Legido-Quigley, Madhav Thambisetty
BACKGROUND: The metabolic basis of Alzheimer disease (AD) pathology and expression of AD symptoms is poorly understood. Omega-3 and -6 fatty acids have previously been linked to both protective and pathogenic effects in AD. However, to date little is known about how the abundance of these species is affected by differing levels of disease pathology in the brain. METHODS AND FINDINGS: We performed metabolic profiling on brain tissue samples from 43 individuals ranging in age from 57 to 95 y old who were stratified into three groups: AD (N = 14), controls (N = 14) and "asymptomatic Alzheimer's disease" (ASYMAD), i...
March 2017: PLoS Medicine
keyword
keyword
63208
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"